I-Mab and VMS Partner to IPO a SPAC in HK for a China Life Science Company
publication date: Apr 26, 2022
Shanghai I-Mab and one of its investors, VMS, have filed for a Hong Kong IPO of a SPAC, Vivere Lifesciences Acquisition, that will seek to acquire an innovative China life science company. The target company is expected to be based in China or have “a significant China angle.” VMS will own 52% of the Founder SPAC shares, I-Mab will have a 30% stake, and individuals associated with the two company will own the rest. Usually, the SPAC’s founding members are rewarded with a 20% block of the SPAC’s shares for their work. More details....
Stock Symbol: (NSDQ: IMAB)
Share this with colleagues:
To gain access to the members only content click here to subscribe.
You will be given immediate access to premium content on the site.